Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma
The immune checkpoint inhibitor durvalumab could become a standard part of first-line mesothelioma treatment if the results of a new…
Advancements and progress on mesothelioma studies in Australia may lead patients to better prognosis. Arm yourself with the right knowledge. Learn more.